Literature DB >> 16547014

Origin and funding of the most frequently cited papers in medicine: database analysis.

Nikolaos A Patsopoulos1, John P A Ioannidis, Apostolos A Analatos.   

Abstract

OBJECTIVE: To evaluate changes in the role of academics and the sources of funding for the medical research cited most frequently over the past decade.
DESIGN: Database analysis. DATA SOURCES: Web of Knowledge database.
METHODS: For each year from 1994 to 2003, articles in the domain of clinical medicine that had been cited most often by the end of 2004 were identified. Changes in authors' affiliations and funding sources were evaluated.
RESULTS: Of the 289 frequently cited articles, most had at least one author with a university (76%) or hospital (57%) affiliation, and the proportion of articles with each type of affiliation was constant over time. Government or public funding was most common (60% of articles), followed by industry (36%). The proportion of most frequently cited articles funded by industry increased over time (odds ratio 1.17 per year, P = 0.001) and was equal to the proportion funded by government or public sources by 2001. 65 of the 77 most cited randomised controlled trials received funding from industry, and the proportion increased significantly over time (odds ratio 1.59 per year, P = 0.003). 18 of the 32 most cited trials published after 1999 were funded by industry alone.
CONCLUSION: Academic affiliations remain prominent among the authors of the most frequently cited medical research. Such research is increasingly funded by industry, often exclusively so. Academics may be losing control of the clinical research agenda.

Keywords:  Biomedical and Behavioral Research; Empirical Approach

Mesh:

Year:  2006        PMID: 16547014      PMCID: PMC1458565          DOI: 10.1136/bmj.38768.420139.80

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  22 in total

1.  Assessing faculty financial relationships with industry: A case study.

Authors:  E A Boyd; L A Bero
Journal:  JAMA       Date:  2000-11-01       Impact factor: 56.272

Review 2.  Scope and impact of financial conflicts of interest in biomedical research: a systematic review.

Authors:  Justin E Bekelman; Yan Li; Cary P Gross
Journal:  JAMA       Date:  2003 Jan 22-29       Impact factor: 56.272

3.  Academic medicine: the evidence base.

Authors: 
Journal:  BMJ       Date:  2004-10-02

4.  NIH funding. Success rates squeezed as budget growth slows.

Authors:  Jocelyn Kaiser
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

5.  Relative citation impact of various study designs in the health sciences.

Authors:  Nikolaos A Patsopoulos; Apostolos A Analatos; John P A Ioannidis
Journal:  JAMA       Date:  2005-05-18       Impact factor: 56.272

6.  Problems with co-funding in Canada.

Authors:  Mike Tyers; Eric Brown; David W Andrews; John J M Bergeron; Charles Boone; Roderick Bremner; Howard A Bussey; James C Cross; Julian E Davies; Michel Desjardins; John E Dick; Daniel J Dumont; Daniel Durocher; Michael J Ellison; G Brian Golding; Michael W Gray; Lea A Harrington; Philip A Hieter; Gerald Johnston; David J Kelvin; Brian E McCarry; Stephen W Michnick; Francis Ouellette; Ron E Pearlman; Linda J Z Penn; Jerry Pelletier; Richard A Rachubinski; Paul S Rennie; Daniela Rotin; Robert Rottapel; Ivan Sadowski; Frank Sicheri; Lou Siminovitch; Nahum Sonenberg; K W Michael Siu; Michel L Tremblay; Neil Winegarden; Richard W Wozniak; Gerard D Wright; James R Woodgett
Journal:  Science       Date:  2005-06-24       Impact factor: 47.728

7.  Restoring balance to industry-academia relationships in an era of institutional financial conflicts of interest: promoting research while maintaining trust.

Authors:  Michael M E Johns; Mark Barnes; Patrik S Florencio
Journal:  JAMA       Date:  2003-02-12       Impact factor: 56.272

8.  Five futures for academic medicine.

Authors:  Shally Awasthi; Jil Beardmore; Jocalyn Clark; Philip Hadridge; Hardi Madani; Ana Marusic; Gretchen Purcell; Margaret Rhoads; Karen Sliwa-Hähnle; Richard Smith; Tessa Tan-Torres Edejer; Peter Tugwell; Tim Underwood; Robyn Ward
Journal:  PLoS Med       Date:  2005-07-05       Impact factor: 11.069

9.  Medical journals are an extension of the marketing arm of pharmaceutical companies.

Authors:  Richard Smith
Journal:  PLoS Med       Date:  2005-05-17       Impact factor: 11.069

10.  Curbing the influence of the drug industry: a British view.

Authors:  Richard Smith
Journal:  PLoS Med       Date:  2005-08-02       Impact factor: 11.069

View more
  38 in total

1.  Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals.

Authors:  F Alfonso; A Timmis; F J Pinto; G Ambrosio; H Ector; P Kulakowski; P Vardas
Journal:  Neth Heart J       Date:  2012-06       Impact factor: 2.380

2.  Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis.

Authors:  Nasim A Khan; Juan I Lombeida; Manisha Singh; Horace J Spencer; Karina D Torralba
Journal:  Arthritis Rheum       Date:  2012-07

3.  Sharing hypotheses and ideas in public health research: contributing to the research agenda.

Authors:  Blanca Lumbreras; Ildefonso Hernández-Aguado
Journal:  J Epidemiol Community Health       Date:  2007-01       Impact factor: 3.710

4.  Fraud: causes and culprits as perceived by science and the media. Institutional changes, rather than individual motivations, encourage misconduct.

Authors:  Martina Franzen; Simone Rödder; Peter Weingart
Journal:  EMBO Rep       Date:  2007-01       Impact factor: 8.807

5.  Is society losing control of the medical research agenda?

Authors:  Brendan Delaney
Journal:  BMJ       Date:  2006-03-17

6.  Is the randomized controlled drug trial in Europe lagging behind the USA?

Authors:  Hiddo J Lambers Heerspink; Mirjam J Knol; Robert J W Tijssen; Thed N van Leeuwen; Diederick E Grobbee; Dick de Zeeuw
Journal:  Br J Clin Pharmacol       Date:  2008-12       Impact factor: 4.335

Review 7.  The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication.

Authors:  Gisela Schott; Henry Pachl; Ulrich Limbach; Ursula Gundert-Remy; Klaus Lieb; Wolf-Dieter Ludwig
Journal:  Dtsch Arztebl Int       Date:  2010-04-30       Impact factor: 5.594

8.  Understanding commonly encountered limitations in clinical research: an emergency medicine resident's perspective.

Authors:  Christopher W Jones; Timothy F Platts-Mills
Journal:  Ann Emerg Med       Date:  2011-08-04       Impact factor: 5.721

9.  Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations.

Authors:  Hans-Jürgen Möller; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02       Impact factor: 5.270

10.  Transdisciplinarity as an inference technique to achieve a better understanding in the health and environmental sciences.

Authors:  Matilda Annerstedt
Journal:  Int J Environ Res Public Health       Date:  2010-06-21       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.